Cefotaxime

Cefotaxime

SCHEMBL5441795

CO/N=C(\C(=O)NC1C(=O)N2C(C(=O)O)=C(COC(C)=O)CS[C@H]12)c1csc(N)n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Cefotaxime. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR1I2 O75469 6/20 1.00
▸ MAPT P10636 3/20 1.00
▸ PPARG P37231 2/20 1.00
▸ SLC22A6 Q4U2R8 2/20 1.00
▸ SLC22A8 Q8TCC7 2/20 1.00
▸ SLC22A11 Q9NSA0 2/20 1.00
▸ ALB P02768 1/20 1.00
▸ HTR2C P28335 1/20 0.87
▸ TDP1 Q9NUW8 6/20 0.86
▸ APEX1 P27695 3/20 0.86
▸ ABCC4 O15439 2/20 0.86
▸ HSD17B10 Q99714 2/20 0.86
▸ LMNA P02545 2/20 0.86
▸ L3MBTL1 Q9Y468 2/20 0.86
▸ CYP1A2 P05177 1/20 0.86
▸ PKM P14618 1/20 0.86
▸ ALDH1A1 P00352 1/20 0.86
▸ POLB P06746 1/20 0.86
▸ RECQL P46063 1/20 0.86
▸ NPSR1 Q6W5P4 1/20 0.86

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cefotaxime SCHEMBL5441797 1.00 NR1I2 (1.00) NR1I2MAPTPPARGSLC22A6SLC22A8
Cefotaxime SCHEMBL2220120 1.00 NR1I2 (1.00) NR1I2MAPTPPARGSLC22A6SLC22A8
Cefotaxime SCHEMBL17422140 1.00 NR1I2 (1.00) NR1I2MAPTPPARGSLC22A6SLC22A8
Cefotaxime SCHEMBL1583477 1.00 NR1I2 (1.00) NR1I2MAPTPPARGSLC22A6SLC22A8
Cefotaxime SCHEMBL10748430 1.00 NR1I2 (1.00) NR1I2MAPTPPARGSLC22A6SLC22A8
Cefotaxime SCHEMBL3731937 1.00 NR1I2 (1.00) NR1I2MAPTPPARGSLC22A6SLC22A8
Cefotaxime SCHEMBL9395572 1.00 NR1I2 (1.00) NR1I2MAPTPPARGSLC22A6SLC22A8
Cefotaxime SCHEMBL15410 1.00 NR1I2 (1.00) NR1I2MAPTPPARGSLC22A6SLC22A8
Cefotaxime SCHEMBL14594281 1.00 NR1I2 (1.00) NR1I2MAPTPPARGSLC22A6SLC22A8
Cefotaxime SCHEMBL16072837 1.00 NR1I2 (1.00) NR1I2MAPTPPARGSLC22A6SLC22A8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070004916-A1 Process for the production of cefotaxime sodium WOCKHARDT LIMITED 2007-01-04 — — US claimed
EP-1704153-A2 IMPROVED PROCESS FOR THE PRODUCTION OF CEFOTAXIME SODIUM Wockhardt Limited (IN) 2006-09-27 — — EP claimed
WO-2005076694-A2 IMPROVED PROCESS FOR THE PRODUCTION OF CEFOTAXIME SODIUM WOCKHARDT LIMITED (IN) 2005-08-25 — — WO claimed
EP-0023453-B1 PROCESS FOR THE PREPARATION OF DERIVATIVES OF 7-(2-ARYL)-2-HYDROXYIMINO-ACETAMIDO CEPHALOSPORANIC ACID ROUSSEL-UCLAF (FR) 1983-11-16 — — EP claimed
EP-0001024-B1 CRYSTALLINE FORM OF THE SODIUM SALT OF AN OXYIMINO DERIVATIVE OF THE 7-AMINOTHIAZOLYLACETAMIDO-CEPHALOSPORANIC ACID, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT ROUSSEL-UCLAF (FR) 1981-01-21 — — EP claimed
US-20070004916-A1 Process for the production of cefotaxime sodium WOCKHARDT LIMITED 2007-01-04 — — US disclosed
US-20070004916-A1 Process for the production of cefotaxime sodium WOCKHARDT LIMITED 2007-01-04 — — US disclosed
EP-1704153-A2 IMPROVED PROCESS FOR THE PRODUCTION OF CEFOTAXIME SODIUM Wockhardt Limited (IN) 2006-09-27 — — EP disclosed
EP-1704153-A2 IMPROVED PROCESS FOR THE PRODUCTION OF CEFOTAXIME SODIUM Wockhardt Limited (IN) 2006-09-27 — — EP disclosed
WO-2005076694-A3 IMPROVED PROCESS FOR THE PRODUCTION OF CEFOTAXIME SODIUM WOCKHARDT LTD (IN) 2005-12-01 — — WO disclosed
WO-2005076694-A2 IMPROVED PROCESS FOR THE PRODUCTION OF CEFOTAXIME SODIUM WOCKHARDT LIMITED (IN) 2005-08-25 — — WO disclosed
WO-2005076694-A2 IMPROVED PROCESS FOR THE PRODUCTION OF CEFOTAXIME SODIUM WOCKHARDT LIMITED (IN) 2005-08-25 — — WO disclosed
US-4388316-A BACTERICIDES ELI LILLY AND COMPANY (US) 1983-06-14 — — US disclosed
US-4379787-A ANTIBIOTICS ELI LILLY AND COMPANY (US) 1983-04-12 — — US disclosed
US-4379739-A Electrolytic reduction of cephalosporin p-nitrobenzyl esters ELI LILLY AND COMPANY (US) 1983-04-12 — — US disclosed
EP-0074268-A2 Improvements in or relating to thieno and furopyridinium-substituted cephalosporin derivatives ELI LILLY AND COMPANY (US) 1983-03-16 — — EP disclosed
EP-0060144-A2 Cephalosporin antibiotics ELI LILLY AND COMPANY (US) 1982-09-15 — — EP disclosed
US-4336253-A Cephalosporin antibiotics ELI LILLY AND COMPANY (US) 1982-06-22 — — US disclosed
US-4331666-A BACTERICIDAL CEPHALOSPORIN ANTIBIOTICS FARMITALIA CARLO ERBA S.P.A. (IT) 1982-05-25 — — US disclosed
EP-0049118-A2 Cephalosporin derivatives, their preparation and compositions containing them SANKYO COMPANY LIMITED (JP) 1982-04-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004916-A1 Process for the production of cefotaxime sodium TALDO1, CEPT1, ADH1A NR1I2 4562/4885MAPT 1454/4885PPARG 2995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback